Vir Biotechnology, Inc. $VIR
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-20
ACTIVE TRIALS5
PHASE 3 / 2-32
RECRUITING1
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO60%
Delay Index: of 5 active trials registered more than a year ago, 3 have moved their primary completion (readout) date by more than 6 months since first registration (median +15.7 months). See all sponsors →
Open Vir Biotechnology, Inc. on the live radar map → 📅 $VIR readout calendar (.ics)| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Tobevibart NCT06903338 |
P3 | Active, not recruiting | Viral Hepatitis | 124 | 2026-09-30 (-3 mo) |
| Tobevibart NCT07128550 |
P3 | Active, not recruiting | Viral Hepatitis | 150 | 2026-12 |
| VIR-5818 NCT05356741 |
P1/2 | Recruiting | Locally Advanced or Metastatic HER2-Expressing Cancers | 645 | 2028-04 (+16 mo) |
| Tobevibart NCT07142811 |
P2 | Active, not recruiting | Viral Hepatitis | 100 | 2029-03 (+28 mo) |
| VIR-2218 NCT05461170 |
P2 | Active, not recruiting | Hepatitis D, Chronic | 95 | 2031-11 (+59 mo) |